**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 5526**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (6): *Helicobacter pylori*

**Current progress toward eradicating *Helicobacter pylori* in East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South Korea**

Lee SY. *H. pylori* eradication in East Asia

Sun-Young Lee

**Sun-Young Lee,** Department of Internal Medicine, Konkuk University School of Medicine, Seoul 143-729, South Korea

**Author contributions:** Lee SY solely contributed to this paper.

**Supported by** Konkuk University

**Correspondence to: Sun-Young Lee, MD, PhD,** Department of Internal Medicine, Konkuk University School of Medicine. 4-12 Hwayang-dong, Gwangjin-gu, Seoul 143-729, South Korea. [sunyoung@kuh.ac.kr](mailto:sunyoung@kuh.ac.kr)

**Telephone:** +82-2-20307505 **Fax:** +82-2-20307505

**Received:** September 13, 2013 **Revised:** November 3, 2013

**Accepted:** January 6, 2014

**Published online:**

**Abstract**

New 2013 guidelines on *Helicobacter pylori* (*H. pylori*)infection have been published in China, Japan, and South Korea. Like the previous ones, these new guidelines differ between the three countries with regard to the indications for *H. pylori* eradication, diagnostic methods, and treatment regimens. The most profound change among all of the guidelines is that the Japanese national health insurance system now covers the expenses for all infected subjects up to second-line treatment. This makes the Japanese indications for eradication much wider than those in China and South Korea. With regard to the diagnosis, a serum *H. pylori* antibody test is not recommended in China, whereas it is considered to be the most reliable method in Japan. A decrease relative to the initial antibody titer of more than 50% after 6-12 mo is considered to be the most accurate method for determining successful eradication in Japan. In contrast, only the urea breath test is recommended after eradication in China, while either noninvasive or invasive methods (except the bacterial culture) are recommended in South Korea. Due to the increased rate of antibiotics resistance, first-line treatment is omitted in China and South Korea in cases of clarithromycin resistance. Notably, the Japanese regimen consists of a lower dose of antibiotics for a shorter duration (7 d) than in the other countries. There is neither 14 d nor bismuth-based regimen in the first-line and second-line treatment in Japan. Such differences among countries might be due to differences in the approvals granted by the governments and national health insurance system in each country. Further studies are required to achieve the best results in the diagnosis and treatment of *H. pylori* infection based on cost-effectiveness in East Asian countries.

©2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** *Helicobacter pylori*; Eradication; Guideline; Diagnosis; Treatment

**Core tip:** Considerable advances in shifting from secondary prevention to primary prevention of gastric cancer are notable in the new 2013 guidelines from China, Japan, and South Korea. Compared to the previous guidelines, indications for *Helicobacter pylori* (*H. pylori*) eradication have expanded to include younger populations with acute gastric lesions, who will show markedly greater improvements than older populations with chronic gastric lesions. The indications of eradication, diagnostic methods, and treatment regimens for *H. pylori* infection differ between the countries due to differences in the approvals granted by the governments and national health insurance system in each country.

Lee SY. Current progress toward eradicating *Helicobacter pylori* in East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South Korea.

**Available from:**

**DOI:**

**INTRODUCTION**

East Asian countries such as China, Japan, and South Korea are the high risk countries of *Helicobacter pylori* (*H. pylori*) infection and gastric cancer. Debates have been continued on whether to eliminate *H. pylori* in all infected East Asians by revising the guidelines, because everyone with *H. pylori* infection would be better eradicated at a reversible stage before the development of precancerous conditions[1].*H. pylori* tend to be more virulent East-Asian type cagA strain in these countries, and thus concerns were raised with regard to the previous guidelines that indicate to eliminate *H. pylori* only for some, leaving many infected East Asians untreated [2-4].

The new revised 2013 guidelines from China, Japan, and South Korea show expanded indications for *H. pylori* eradication[5-7]. These new guidelines started to include more recent infections at the acute stage that has not yet progressed to the irreversible stage leading to gastric cancer. Based on these guidelines, it is believed that strategy for the prevention of gastric cancer will shift from secondary prevention using esophagogastroduodenoscopy (EGD) to primary prevention using *H. pylori* eradication in East Asians. In this review, recent trends on *H. pylori* eradication in the East Asian countries will be discussed in terms of (1) indications, (2) diagnostic methods, (3) therapeutic regimens, and (4) issues after eradication based on the new 2013 guidelines.

**INDICATIONS FOR *H. PYLORII* ERADICATION**

Revised guidelines published in 2013 include more of the *H. pylori*-infected stomachs than the previous ones (Table 1)[5-7]. Previous East Asian guidelines on *H. pylori* eradication were mainly focus low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma, peptic ulcer disease (PUD), after the resection of early gastric cancer (EGC), idiopathic thrombocytopenic purpura (ITP), iron deficiency anemia (IDA) of uncertain origin, and long-term use of certain drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or proton pump inhibitor (PPI)[2-4]. However, new indications include even the asymptomatic *H. pylori*-infected subjects based on the concept that the benefits of eradication for gastric cancer prevention outweigh the risks.

***China***

The Fourth National Consensus Conference on the management of *H. pylori* infection consists of 3 categories: (1) detection; (2) indication; and (3) regimen for eradication[6]. Indications for *H. pylori* eradication consist of 2 strongly recommended diseases (PUD and gastric MALT lymphoma) and 10 recommended diseases as summarized in Table 1. It is notable that *H. pylori*-related diseases consist of lymphocytic gastritis, Ménétrier disease, and gastric hyperplastic polyps[8]. Intestinal metaplasia (IM) is not included based on the concept that it is hard to reverse IM[9]. Their analysis also revealed that *H. pylori* eradication improves chronic atrophy gastritis (CAG) only in the gastric body.

***Japan***

The Ministry of Health, Labour and Welfare of Japan announced that the Japanese national health insurance system started to cover the expenses for *H. pylori* eradication in all of the infected subjects from February 2013. The current indications consist of five categories: (1) PUD; (2) after resection of EGC; (3) Gastric MALT lymphoma; (4) ITP;and (5) *H. pylori*-related gastritis (<http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iryouhoken>). These expanded indications are not only for the prevention of *H. pylori*-related diseases such as gastric cancer but also for the prevention of dissemination. Since infection seems to disseminate from the parents to a child during the childhood period, dissemination of *H. pylori* can be prevented by eradicating all infected adults[7].

Japanese cohort studies and randomized control trial on the effect of *H. pylori* eradication in preventing gastric cancers have shown that it would more benefit in earlier ages and even in subjects with CAG and/or MG before it progress further[10-15]. Although open-type CAG and MG seem to be more progressed toward gastric carcinogenesis than closed-type CAG and nonatrophic/nonmetaplastic cases[16], there is still a chance for incomplete-type IM to changed to a milder complete-type IM after eradication[17]. When *H. pylori* eradication therapy is performed before the 30 years-old, the effect on gastric cancer prevention is near 100%, but it decreases to 41% in men and 71% in women when the eradication is performed after 70 years-old[7,18,19].

Of various “*H. pylori*-related gastritis”, CAG, metaplastic gastritis (MG), hypertrophic gastritis (HG), and nodular gastritis (NG) are considered significant with regard to gastric carcinogenesis. CAG and MG are endoscopic findings of chronic *H. pylori* infection, while NG and HG are those of recent infection[20]. In NG, inflammatory cytokines and *H. pylori*-infection-induced prostaglandins are normalized after eradication[21]. Without eradication, some progress to a diffuse-type nodular gastritis, MALT lymphoma, or adenocarcinoma with poor differentiation[22]. Besides, the odds ratio for gastric carcinoma is increases up to 35.5 in HG due to the increased levels of 8-Hydroxy-2-deoxy guanosine and interleukin-1 beta in the gastric mucosa[23]. Similar to NG, *H. pylori* eradication is highly recommended for HG because the mutagenicity of gastric juice and the methylation of E-cadherin in gastric mucosa decrease significantly after eradication[23,24].

In May 2013, the “Kyoto Guideline on the Endoscopic Gastritis” was announced at the Annual conference of Japanese Society of Gastrointestinal Endoscopy. According to this guideline, scores for these 4 types of endoscopic gastritis reported as “A M H N (total score)”. For CAG, the scores range from 0-3 according to the extent of the atrophic border. For MG, score 2 is given when metaplastic changes are observed during EGD. When an image-enhanced endoscopy was used for the diagnosis of MG, “(IM)” should be added. For HG, score 1 is given when there is a gastric fold width greater than 7 mm. For NG, score 2 is given when there is a chicken-skin-like nodularity. If there is a history of *H. pylori* eradication, score -1 is subtracted from the total score and recorded as “E-1” after “A M H N”. For example, A3M2(IM2)H0N0E-1(4 scores) means that the subject has an opened-type CAG of severe-degree (3 scores), MG observed by image enhancing endoscopy (2 scores), and underwent a successful *H. pylori* eradication (-1 score). Therefore, score for the risk of gastric cancer is 4, indicating that there is a high risk of intestinal-type gastric cancer in this subject.

***South Korea***

The new South Korean guideline consists of 11 statements for the indication of *H. pylori* eradication, 4 statements for the diagnosis, and 4 statements for the treatment[5]. Highly recommended indications for *H. pylori* eradication are (1) PUD including scar; (2) low-grade gastric MALT lymphoma; (3) after the resection of EGC. Although the level of evidence is lower than these indications, *H. pylori* eradication may be considered for the prevention of gastric cancer in the subjects with (4) CAG or IM; and (5) a family history of gastric cancer. South Korean studies have shown the importance of a family history of gastric cancer especially for those before 40 years-old[25-27]. *H. pylori* eradication is reported to improve severe CAG and IM[28]. Improvement by *H. pylori* eradiation seems to be more definite in patients with body-predominant gastritis, severe IM, or low pepsinogen I/II ratio (Figure 1).Although the *H. pylori* infection rate in South Korea is decreasing[29],care should be taken to prevent gastric carcinogenesis, because most of *H. pylori* isolated in South Koreans possesses virulent East-Asian cagA type as observed in our previous study[30].

According to this new guideline[5], EGD followed by *H. pylori* eradication is recommended for functional dyspepsia (FD) subjects, because eliminating *H. pylori* improves not only the gastritis but also the FD symptoms suggesting that *H. pylori*-induced inflammation mediates FD in the East Asians[31]. There is a view point that FD-related symptoms in the East Asian population should be considered as an organic disease due to *H. pylori* infection which is different from those in the West[32]. Besides, *H. pylori* eradication should be considered in case of long-term aspirin medication to prevent the recurrence of PUD for those who have a history of PUD. Asians are considered to be more prone to bleeding than Caucasians[33], and therefore eradication should be preformed in East Asia where the prevalence of *H. pylori* infection is higher[34]. Furthermore, the risk of PUD recurrence cannot be blocked by *H. pylori* eradication alone in case of long-term NSAIDs/aspirin medication, and thus PPI could be considered. Since acid suppressants accelerate body gastritis in the presence of *H. pylori* infection, it should be eradicated before the long-term use of PPI[35]. In South Korea, eradicating *H. pylori* infection is less expensive and more effective than no-screening strategy in case of NSAIDs and/or aspirin medication[36].

For the extraintestinal diseases, *H. pylori* eradication is indicated for the subjects with ITP[5]. Other extragastric disease is not mentioned in the guideline, but there are several cardiovascular, hepatobiliary, dermatological, immunological, hematological, ophthalmological, and neurologic diseases improve after *H. pylori* eradication[1].

**DIAGNOSTIC METHODS FOR *H. PYLORII* INFECTION**

Diagnosis of *H. pylori* infection in East Asians countries consists of invasive and non-invasive methods like those of the Western countries, but guidelines differ between China, Japan, and South Korea (Table 2). Noninvasive methods are serum *H. pylori* immunoglobulin G (IgG)antibody test, urine antibody test, stool antigen test, and 13C- or 14C-urea breath test (UBT). Invasive methodsare those based on the gastric biopsy specimen using EGD. These include rapid urease test (RUT), bacterial culture, histology (Hematoxylinand Eosin stain, modified Giemsa stain, Genta stain, Warthin–Starry silver stain, toluidine blue stain, *etc.*), and gene detection method such as Fluorescence *in situ* hybridization or polymerase chain reaction for testing resistance to the antibiotics. Due to the low cost of EGD in East Asian countries, invasive tests are frequently performed as noninvasive tests.

***China***

*H. pylori*infection can be diagnosed when there is a positive finding on the: (1) stool antigen test; (2) UBT; or (3) one of the invasive tests among RUT, histology, and culture[6]. Positive serum *H. pylori* antibody is not included in the diagnostic criteria. Serology is used mainly for epidemiological survey and for certain conditions such as PUD bleeding and gastric MALT lymphoma in China. Different from Japan where the decreased antibody titer after 6 to 12 mo is considered as a reliable method in diagnosing successful eradication, serology is not recommended for both pre- and post-treatment re-examination in China.

UBT is recommended as the first choice for post-treatment evaluation of eradication of *H. pylori* infection at least 4 weeks after eradication[6]. The new guideline indicates that *H. pylori* eradication can be diagnosed when there is a negative finding on the: (1) UBT; (2) stool antigen test; or (3) RUT of both samples taken from the gastric body and antrum. At least 4 wk before UBT, bismuth agents, antibiotics, or herbal medicines with antibiotic activity should be stopped. Acid suppressants should be stopped at least 2 wk before UBT, if any. Urease-dependent tests are not recommended for bleeding PUD, severe CAG, after gastrectomy, and gastric malignancy. For histology, the guideline denotes that *H. pylori* infection is highly suggestive even in the absence of organism when there is an active inflammation in IM.

***Japan***

The most reliable method for the confirmation of *H. pylori* infection is considered as the titer of serum *H. pylori* IgG antibody in Japan[7,18,19]. Either 1 of 3 invasive methods (RUT, culture, or histology with either Giemsa, Warthin-Starry, Genta stain, *etc*.) or 2 of 3 noninvasive methods (serum *H. pylori* antibody, UBT, and stool antigen test) are covered by the Japanese national health insurance system. For the initial diagnosis, both RUT and histology can be covered at the same time, but not thereafter. A combination of 2 noninvasive methods is preferred than 1 invasive test, because the accuracies of invasive tests are lower than those of noninvasive tests. After the first-line and second-line eradication therapy, the Japanese national health insurance system covers either 1 of 3 invasive methods or 2 of 3 noninvasive methods, respectively. Successful eradication is considered as more than 50% reduction of serum IgG antibody titer than its initial level after 6-12 mo of eradication.

***South Korea***

Recommendations for the diagnosis includes either one of the noninvasive methods (UBT, stool antigen test, or serum *H. pylori* IgG antibody test) or invasive methods (RUT or gastric biopsy for histology) as noninvasive methods[5]. For invasive methods, it is recommended to take both samples at the antrum and body, and to biopsy the sites that show the least atrophic and metaplastic findings. Follow-up tests after eradication include UBT, stool antigen test, RUT, or histology after 4 wk. Acid suppressants are asked to be stopped at least 2 wk before UBT.

**THERAPEUTIC REGIMENS FOR *H. PYLORII* ERADICATION**

Increased use of antibiotics for various infections since childhood has resulted in increasing drug resistance and decreasing in *H. pylori* eradication rate using clarithromycin or metronidazole. The increased primary and secondary antibiotic resistance of *H. pylori* is different according to the region, and therefore the current recommended first-line therapy and second-line therapy are different between China, Japan, and South Korea (Table 3). There is no standard for third-line therapy in these guidelines, and thus (1) regimens including levofloxacin, moxifloxacin, or rifabutin; (2) sequential therapy; (3) concomitant therapy; (4) dual therapy; or (5) tailored therapy might be considered as alternatives.

***China***

Standard triple therapy using amoxicillin (or metronidazole), clarithromycin, and PPI twice a day for 7 to 14 d are recommended for first-line treatment[6]. However, the eradication rate of this triple therapy in China is below 80%. Some studies showed that individualized therapy should be done based on the region of the China indicating the antibiotic resistance, patient occupation, gender, and compliance[37,38]. The resistance rates to metronidazole (60%–70%), clarithromycin (20%–38%), and levofloxacin (30%–38%) are higher than amoxicillin, furazolidone, and tetracycline (1%–5%)[39]. As an alternative regimen, levofloxacin triple therapy (PPI, levofloxacin, and amoxicillin) or sequential therapy (5 d of PPI and amoxicillin followed by 5 d of PPI, clarithromycin, and metronidazole) is recommended. However, concomitant therapy (PPI, clarithromycin, amoxicillin, and metronidazole) is used only if the patients have the contraindication for bismuth.

In regions with high clarithromycin resistance rate over 15%–20%, bismuth quadruple therapy (bismuth, tetracycline, metronidazole, and PPI for 10 or 14 d) is recommended as a first-line treatment[6]. In such cases, second-line treatments are used from the beginning without using first-line treatment. To overcome the resistance to metronidazole and clarithromycin, combined use of bismuth and PPI are usually recommended. Other quadruple regimens consist of a a standard dose of PPI, bismuth potassium citrate 220 mg, and 2 different antibiotics twice daily for 10 or 14 d: (1) amoxicillin 1000 mg and clarithromycin 500 mg twice daily; (2) amoxicillin 1000 mg and levofloxacin 200 mg twice daily (or 500 mg once daily); (3) amoxicillin 1000 mg and furazolidone 100 mg twice daily; (4) tetracycline 750 mg and metronidazole 400 mg twice daily (or thrice daily); and (5) tetracycline 750 mg and furazolidone 100 mg twice daily[6,40]. A recent Chinese study showed the efficacy and safety of traditional Chinese medicine for *H. pylori* eradication by reviewing 16 clinical trials[41]. However, there was no significant effect of traditional Chinese medicine for *H. pylori* treatment as triple regimen, and therefore it is not recommended alone for *H. pylori* eradication.

***Japan***

Japanese treatment regimen consists of lower dose of antibiotics than other countries[7,42].For first-line treatment, a standard dose of PPI, amoxicillin 750 mg, and clarithromycin 200 mg (or 400 mg) are recommended twice daily for 7 d. For second-line treatment, PPI, amoxicillin 750 mg, and metronidazole 250 mg are recommended twice daily for 7 d. Neither 14 d nor bismuth-based quadruple treatment has been recommended as first-line or second-line treatment in Japan.

The eradication rate of the first-line regimen is 70% and that of the second-line regimen is 90% in Japan, and thus the eradication rate exceeds 95% with these two regimens[42,43]. There is no standard recommendation for the third-line treatment in Japan. Moreover, the Japanese national health insurance system does not cover after second-line treatment. Regimens such as (1) high-dose amoxicillin with PPI; or (2) quinolone with amoxicillin and PPI are often used for the third-line treatment[44]. Third-line treatment regimens preferred by the Japanese doctors are (1) amoxicillin 500 mg 3 or 4 times daily, ciprofloxacin 100 mg twice daily, and PPI 2-4 times daily for 1-2 wk; (2) metronidazole 250 mg twice daily, ciprofloxacin 100 mg twice daily, and PPI 2-4 times daily for 1-2 wk; and (3) amoxicillin 500 mg 4 times daily and PPI 4 times daily (with ecarbet natrium 1g) 4 times daily for 2-4 wk as mentioned in page 36 of the Japanese supplement published in April 18th, 2013 by the Japanese Society of *Helicobacter* Research (unpublished data in English).

***South Korea***

For first-line treatment, recommended regimens are a standard dose of PPI, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 7 to 14 d [5]. In cases of treatment failure and with clarithromycin resistance, a standard dose of PPI twice a day, metronidazole 500 mg thrice a day, bismuth 120 mg 4 times a day, and tetracycline 500 mg 4 times a day are recommended for 7 to 14 d. In case of treatment failure with the quadruple therapy, more than two antibiotics that differ from previous regimens are recommended. Phytoceuticals such as South Korean red ginseng, green tea, red wine, flavonoids, broccoli sprouts, garlic, probiotics, and flavonoids are known to inhibit *H. pylori* colonization *H. pylori*-related inflammatory process[45]. However, phytoceuticals are not recommended as a standard treatment in East Asian countries.

The guideline denotes the duration of medication from 7 to 14 d[5]. Notably, the eradication rate second-line treatment differs according to the duration of the treatment. The eradication rate of 2 wk of bismuth-containing quadruple therapy is significantly higher (93.6%) than that of the 1 wk-treatment (77.2%)[46]. In South Korea, the eradication rates of first-line and second-line regimen are decreasing because of the antibiotic resistance rates on amoxicillin (6.3%-14.9%), clarithromycin (17.2%-23.7%), and synchronous levofloxacin and moxifloxacin (4.7%-28.1%)[47]. In addition, continuing genomic diversities in the same *H. pylori* strain may result in the presence of simultaneous antibiotic-susceptible and -resistant *H. pylori* in the same host, and modulate heteroresistant antibacterial phenotypes in South Korean adults[48]. Such an isogenic variation of *H. pylori* strain in a single host would be one of the reasons of treatment failure.

**ISSUES AFTER THE SUCCESSFUL ERADICATION**

After the eradication, it is important to inform the patients that there is a risk of false-negative finding, gastric cancer, GERD, and reinfection. The rates of reinfection are decreasing in East Asian countries due to the improved sanitization and socioeconomic status. Recent studies showed that reinfection rate is lower in Japan (0.22% per year) than China (2.82%) and South Korea (2.94%)[49-51]. Male gender (HR = 2.28) and low monthly family income (HR = 3.54) are known as main factors associated with *H. pylori* reinfection[52].

***Gastric cancer after eradication***

*H. pylori* eradication will have the greatest impact on reducing the burden of gastric cancer in the East Asian countries. Based on previous studies and hypotheses that eradication therapy not only inhibits the new occurrence of gastric cancer but also regresses the growth of gastric cancer[10-15], prophylactic eradication is recommended after EGC resection to prevent metachronous gastric carcinoma.However, some will continue to progress toward a gastric cancer even after the eradication because the benefit differs according to the degree of CAG and type of IM (Figure 2). A Japanese study showed that *H. pylori* eradication prior to development of incomplete-type IM improves gastritis in the gastric body[7,18,53]. Eradication seem to be most effective before the significant atrophy develops, but eradication cannot completely prevent EGC even some mild CAG cases[14].Taken altogether, *H. pylori* eradication should be recommended even in high-risk populations with CAG and IM, although it cannot completely abolish the risk of gastric cancer.

The incidence of gastric cancer after a successful eradication is higher in the subjects after gastric cancer resection (10.1%) than gastric ulcer (2.4%), gastric MALT lymphoma (2.2%), chronic gastritis (1.6%), and duodenal ulcer (0.3%)[18,19].Therefore, regular EGD follow-up is usually recommended after eradication. In South Korea, most of the physicians recommend annual EGD follow-up to the subjects with CAG and IM regardless of their career, position, and degree of the hospital[54].

***Gastroesophageal reflux disease after eradication***

There is still a controversy on the link between *H. pylori* and GERD. Although some GERDs are improved by *H. pylori* eradication[55], some develop after eradication[56,57]. Care should be taken because hyperacidity-related diseases such as GERD and erosive gastroduodenitis after *H. pylori* eradication seem to occur more often in Easterncountries due to increased gastric acid secretion in body-dominant gastritis. In a prospective post-eradication study on 1195 *H. pylori-*positive BGU patients, GERD developed in 279 of 1000 successfully eradicated cases after a mean follow-up period of 3.6 years[57]. Most of newly developed GERD was mild (Los Angeles grade A) and transient, and most did not require long-term treatment in their study. Different from Japanese studies, large-sized study from South Korea and meta-analysis on 11 papers from China show that there is no link between *H. pylori* eradication and GERD[58,59]. Taken as a whole, *H. pylori* eradication therapy should not be withheld for fear of GERD development in the East Asia.

The prevalence of GERD might be increased due to obesity after the physiological changes that happen after eradication. *H. pylori* infection increases gastric leptin by reducing ghrelin-producing cells in the gastric mucosa[60]. As a result, *H. pylori* influences body weight, hunger, and satiety, and thus affect the pathophysiology of obesity[61]. After eradication, subjects show increased gastric emptying and increased appetite due to increased ghrelin level[62].

**CONCLUSION**

The new 2013 guidelines from China, Japan, and South Korea reflect the current progress toward eradicating *H. pylori* among East Asians. Compared to the previous guidelines, indications for *H. pylori* eradication have expanded to include younger populations with acute gastric lesions, who will show markedly greater improvements than older populations with chronic gastric lesions. Considerable advances in shifting from secondary prevention to primary prevention of gastric cancer are notable in these new guidelines. It is also notable that the indications of eradication, diagnostic methods, and treatment regimens for *H. pylori* infection differ between the countries (Table 4), despite similarities in the prevalence rates of *H. pylori* infection and gastric cancer. Such differences among countries might be due to differences in the approvals granted by the governments and national health insurance system in each country. Further studies are required to providedirections for identifying the optimal (1) diagnostic method with low false-negative rates, (2) treatment regimen to overcome antibiotic resistance, and (3) follow-up strategy after *H. pylori* eradication based on cost-effectiveness in East Asian countries.

**REFERENCES**

1 **Lee SY**. Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised? *J Gastroenterol Hepatol* 2012; **27**: 200-211 [PMID: 22098099 DOI: 10.1111/j.1440-1746.2011.06961.x]

2 **Hu FL**, Hu PJ, Liu WZ, De Wang J, Lv NH, Xiao SD, Zhang WD, Cheng H, Xie Y. Third Chinese National Consensus Report on the management of Helicobacter pylori infection. *J Dig Dis* 2008; **9**: 178-184 [PMID: 18956598 DOI: 10.1111/j.1751-2980.2008.00342.x]

3 **Asaka M**, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. *Helicobacter* 2010; **15**: 1-20 [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x]

4 **Kim N,** Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Association of Gastroenterology. [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. *Korean J Gastroenterol* 2009; **54**: 269-278 [PMID: 19934608 DOI: 10.4166/kjg.2009.54.5.269]

5 **Kim SG**, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. *Korean J Gastroenterol* 2013; **62**: 3-26 [PMID: 23954956 DOI: 10.4166/kjg.2013.62.1.3]

6[**Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori**](http://www.ncbi.nlm.nih.gov/pubmed?term=Chinese%20Society%20of%20Gastroenterology%2C%20Chinese%20Study%20Group%20on%20Helicobacter%20pylori%5BCorporate%20Author%5D)**,** Liu WZ, Xie Y, Cheng H, Lu NH, Hu FL, Zhang WD, Zhou LY, Chen Y, Zeng ZR, Wang CW, Xiao SD, Pan GZ, Hu PJ. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. *J Dig Dis* 2013; **14**: 211-221 [PMID: 23302262 DOI: 10.1111/1751-2980.12034]

7 **Asaka M**. A new approach for elimination of gastric cancer deaths in Japan. *Int J Cancer* 2013; **132**: 1272-1276 [PMID: 23180638 DOI: 10.1002/ijc.27965]

8 **Ji F**, Wang ZW, Ning JW, Wang QY, Chen JY, Li YM. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. *World J Gastroenterol* 2006; **12**: 1770-1773 [PMID: 16586550 DOI: 0.3748/wjg.v12.i11.1770]

9 **Wang J**, Xu L, Shi R, Huang X, Li SW, Huang Z, Zhang G. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. *Digestion* 2011; **83**: 253-260 [PMID: 21282951 DOI: 10.1159/000280318]

10 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]

11 **Yanaoka K**, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, Inoue I, Iguchi M, Maekita T, Ueda K, Utsunomiya H, Tamai H, Fujishiro M, Iwane M, Takeshita T, Mohara O, Ichinose M. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. *Int J Cancer* 2009; **125**: 2697-2703 [PMID: 19610064 DOI: 10.1002/ijc.24591]

12 **Takenaka R**, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, Miyoshi M, Yumoto E, Imagawa A, Toyokawa T, Sakaguchi K, Shiratori Y. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. *Aliment Pharmacol Ther* 2007; **25**: 805-812 [PMID: 17373919 DOI: 10.1111/j.1365-2036.2007.03268.x]

13 **Ogura K**, Hirata Y, Yanai A, Shibata W, Ohmae T, Mitsuno Y, Maeda S, Watabe H, Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Omata M. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. *J Clin Gastroenterol* 2008; **42**: 279-283 [PMID: 18223496 DOI: 10.1097/01.mcg.0000248006.80699.7f]

14 **Take S**, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, Oguma K, Okada H, Yamamoto K. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. *J Gastroenterol* 2011; **46**: 318-324 [PMID: 21103997 DOI: 10.1007/s00535-010-0347-9]

15 **Fukase K**, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet* 2008; **372**: 392-397 [PMID: 18675689 DOI: 10.1016/S0140-6736(08)61159-9]

16 **Ahn SY**, Lee SY, Hong SN, Kim JH, Sung IK, Park HS, Shim CS, Jin CJ, Han HS. Endoscopic diagnosis of open-type atrophic gastritis is related to the histological diagnosis of intestinal metaplasia and Cdx2 expression. *Dig Dis Sci* 2011; **56**: 1119-1126 [PMID: 21221798 DOI: 10.1007/s10620-010-1531-8]

17 **Watari J**, Das KK, Amenta PS, Tanabe H, Tanaka A, Geng X, Lin JJ, Kohgo Y, Das KM. Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. *Clin Gastroenterol Hepatol* 2008; **6**: 409-417 [PMID: 18321787 DOI: 10.1016/j.cgh.2007.12.044]

18 **Kato M**, Asaka M. Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. *Jpn J Clin Oncol* 2010; **40**: 828-837 [PMID: 20736219 DOI: 10.1093/jjco/hyq119]

19 **Kato M**, Asaka M. Recent development of gastric cancer prevention. *Jpn J Clin Oncol* 2012; **42**: 987-994 [PMID: 23018579 DOI: 10.1093/jjco/hys151]

20 **Lee SY**. Endoscopic gastritis: what does it mean? *Dig Dis Sci* 2011; **56**: 2209-2211 [PMID: 21503678 DOI: 10.1007/s10620-011-1703-1]

21 **Shimatani T**, Inoue M, Iwamoto K, Hyogo H, Yokozaki M, Saeki T, Tazuma S, Horikawa Y, Harada N. Gastric acidity in patients with follicular gastritis is significantly reduced, but can be normalized after eradication for Helicobacter pylori. *Helicobacter* 2005; **10**: 256-265 [PMID: 15904484 DOI: 10.1111/j.1523-5378.2005.00318.x]

22 **Choi HJ,** Lee SY, Lee JH, Seol DC, Kim SY, Choi HJ, Park HS, Hong SN, Han HS. Two atypical cases of nodular gastritis: a poorly differentiated gastric adenocarcinoma and a pseudo-low grade gastric MALT lymphoma. *Gastroenterol Res* 2010; **3**: 41-45 [DOI: 10.4021/gr2010.02.170w]

23 **Nishibayashi H**, Kanayama S, Kiyohara T, Yamamoto K, Miyazaki Y, Yasunaga Y, Shinomura Y, Takeshita T, Takeuchi T, Morimoto K, Matsuzawa Y. Helicobacter pylori-induced enlarged-fold gastritis is associated with increased mutagenicity of gastric juice, increased oxidative DNA damage, and an increased risk of gastric carcinoma. *J Gastroenterol Hepatol* 2003; **18**: 1384-1391 [PMID: 14675267 DOI: 10.1046/j.1440-1746.2003.03192.x]

24 **Miyazaki T**, Murayama Y, Shinomura Y, Yamamoto T, Watabe K, Tsutsui S, Kiyohara T, Tamura S, Hayashi N. E-cadherin gene promoter hypermethylation in H. pylori-induced enlarged fold gastritis. *Helicobacter* 2007; **12**: 523-531 [PMID: 17760721 DOI: 10.1111/j.1523-5378.2007.00519.x]

25 **Shin CM**, Kim N, Yang HJ, Cho SI, Lee HS, Kim JS, Jung HC, Song IS. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. *J Clin Gastroenterol* 2010; **44**: e34-e39 [PMID: 19561529 DOI: 10.1097/MCG.0b013e3181a159c4]

26 **Nam JH**, Choi IJ, Cho SJ, Kim CG, Lee JY, Nam SY, Park SR, Kook MC, Nam BH, Kim YW. Helicobacter pylori infection and histological changes in siblings of young gastric cancer patients. *J Gastroenterol Hepatol* 2011; **26**: 1157-1163 [PMID: 21392104 DOI: 10.1111/j.1440-1746.2011.06717.x]

27 **Chang YW**, Han YS, Lee DK, Kim HJ, Lim HS, Moon JS, Dong SH, Kim BH, Lee JI, Chang R. Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients. *Int J Cancer* 2002; **101**: 469-474 [PMID: 12216076 DOI: 10.1002/ijc.10637]

28 **Kang JM**, Kim N, Shin CM, Lee HS, Lee DH, Jung HC, Song IS. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication: a three-year follow-up study in Korea. *Helicobacter* 2012; **17**: 86-95 [PMID: 22404438 DOI: 10.1111/j.1523-5378.2011.00918.x]

29 **Lee SY**, Park HS, Yu SK, Sung IK, Jin CJ, Choe WH, Kwon SY, Lee CH, Choi KW. Decreasing prevalence of Helicobacter pylori infection: a 9-year observational study. *Hepatogastroenterology* 2007; **54**: 630-633 [PMID: 17523338]

30 **Seo TH**, Lee SY, Uchida T, Fujioka T, Jin CJ, Hwang TS, Han HS. The origin of non-H. pylori-related positive Giemsa staining in human gastric biopsy specimens: A prospective study. *Dig Liver Dis* 2011; **43**: 23-27 [PMID: 20483675 DOI: 10.1016/j.dld.2010.04.006]

31 **Kim SE**, Park YS, Kim N, Kim MS, Jo HJ, Shin CM, Lee SH, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC. Effect of Helicobacter pylori Eradication on Functional Dyspepsia. *J Neurogastroenterol Motil* 2013; **19**: 233-243 [PMID: 23667755 DOI: 10.5056/jnm.2013.19.2.233]

32 **Suzuki H**, Nishizawa T, Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? *J Gastroenterol Hepatol* 2011; **26 Suppl 3**: 42-45 [PMID: 21443708 DOI: 10.1111/j.1440-1746.2011.06629.x]

33 **Lee SY**, Tang SJ, Rockey DC, Weinstein D, Lara L, Sreenarasimhaiah J, Choi KW ; South Korean Association for the Study of Intestinal Disease. Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the East and the West. *Gastrointest Endosc* 2008; **67**: 1076-1081 [PMID: 18384789 DOI: 10.1016/j.gie.2007.11.037]

34 **Lee SY**. Differences in managing anticoagulants and antiplatelets for gastrointestinal endoscopy between East and West. *Gastroenterol Res* 2009; **2**: 67-80. [DOI: 10.4021/gr2009.04.1283]

35 **Kuipers EJ**, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, Nelis GF, Meuwissen SG. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. *N Engl J Med* 1996; **334**: 1018-1022 [PMID: 8598839 DOI: 10.1056/NEJM199604183341603]

36 **Song HJ**, Kwon JW, Kim N, Park YS. Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin. *Gut Liver* 2013; **7**: 182-189 [PMID: 23560154 DOI: 10.5009/gnl.2013.7.2.182]

37 **Cai W**, Zhou L, Ren W, Deng L, Yu M. Variables influencing outcome of Helicobacter pylori eradication therapy in South China. *Helicobacter* 2009; **14**: 91-96 [PMID: 19751433 DOI: 10.1111/j.1523-5378.2009.00718.x]

38 **Su P**, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. *Helicobacter* 2013; **18**: 274-279 [PMID: 23418857 DOI: 10.1111/hel.12046]

39 **Sun QJ**, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. *World J Gastroenterol* 2010; **16**: 5118-5121 [PMID: 20976850 DOI: 10.3748/wjg.v16.i40.5118]

40 **Sun Q**, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. *Helicobacter* 2010; **15**: 233-238 [PMID: 20557366 DOI: 10.1111/j.1523-5378.2010.00758.x]

41 **Lin J**, Huang WW. A systematic review of treating Helicobacter pylori infection with Traditional Chinese Medicine. *World J Gastroenterol* 2009; **15**: 4715-4719 [PMID: 19787835 DOI: 10.3748/wjg.15.4715]

42 **Horiki N**, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. *Helicobacter* 2009; **14**: 86-90 [PMID: 19751432 DOI: 10.1111/j.1523-5378.2009.00714.x]

43 **Shimoyama T**, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. *J Gastroenterol* 2004; **39**: 927-930 [PMID: 15549444 DOI: 10.1007/s00535-004-1424-8]

44 **Shiota S**, Murakawi K, Suzuki R, Fujioka T, Yamaoka Y. Helicobacter pylori infection in Japan. *Expert Rev Gastroenterol Hepatol* 2013; **7**: 35-40 [PMID: 23265147 DOI: 10.1586/egh.12.67]

45 **Lee SY**, Shin YW, Hahm KB. Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. *J Dig Dis* 2008; **9**: 129-139 [PMID: 18956590 DOI: 10.1111/j.1751-2980.2008.00334.x]

46 **Lee BH**, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. *Helicobacter* 2010; **15**: 38-45 [PMID: 20302588 DOI: 10.1111/j.1523-5378.2009.00735.x]

47 **Lee JW**, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. *Helicobacter* 2013; **18**: 206-214 [PMID: 23241101 DOI: 10.1111/hel.12031]

48 **Lee YC**, Lee SY, Pyo JH, Kwon DH, Rhee JC, Kim JJ. Isogenic variation of Helicobacter pylori strain resulting in heteroresistant antibacterial phenotypes in a single host in vivo. *Helicobacter* 2005; **10**: 240-248 [PMID: 15904482 DOI: 10.1111/j.1523-5378.2005.00316.x]

49 **Take S**, Mizuno M, Ishiki K, Imada T, Okuno T, Yoshida T, Yokota K, Oguma K, Kita M, Okada H, Yamamoto K. Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan. *J Gastroenterol* 2012; **47**: 641-646 [PMID: 22350696 DOI: 10.1007/s00535-012-0536-9]

50 **Yan TL**, Hu QD, Zhang Q, Li YM, Liang TB. National rates of Helicobacter pylori recurrence are significantly and inversely correlated with human development index. *Aliment Pharmacol Ther* 2013; **37**: 963-968 [PMID: 23550618 DOI: 10.1111/apt.12293]

51 **Lee JH**, Kim N, Chung JI, Kang KP, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Long-term follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea. *Helicobacter* 2008; **13**: 288-294 [PMID: 18665939 DOI: 10.1111/j.1523-5378.2008.00616.x]

52 **Kim MS**, Kim N, Kim SE, Jo HJ, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JM, Jung HC. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. *Helicobacter* 2013; **18**: 135-142 [PMID: 23066652 DOI: 10.1111/hel.12018]

53 **Shiotani A**, Uedo N, Iishi H, Tatsuta M, Ishiguro S, Nakae Y, Kamada T, Haruma K, Merchant JL. Re-expression of sonic hedgehog and reduction of CDX2 after Helicobacter pylori eradication prior to incomplete intestinal metaplasia. *Int J Cancer* 2007; **121**: 1182-1189 [PMID: 17520681 DOI: 10.1002/ijc.22835]

54 **Shin WG**, Kim HU, Song HJ, Hong SJ, Shim KN, Sung IK, Kim JG; South Korean College of Helicobacter and Upper Gastrointestinal Research. Surveillance strategy of atrophic gastritis and intestinal metaplasia in a country with a high prevalence of gastric cancer. *Dig Dis Sci* 2012; **57**: 746-752 [PMID: 21984437 DOI: 10.1007/s10620-011-1919-0]

55 **Hirata K**, Suzuki H, Matsuzaki J, Masaoka T, Saito Y, Nishizawa T, Iwasaki E, Fukuhara S, Okada S, Hibi T. Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy. *J Clin Biochem Nutr* 2013; **52**: 172-178 [PMID: 23524980 DOI: 10.3164/jcbn.12-107]

56 **Nam SY**, Choi IJ, Ryu KH, Kim BC, Kim CG, Nam BH. Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. *Am J Gastroenterol* 2010; **105**: 2153-2162 [PMID: 20571493 DOI: 10.1038/ajg.2010.251]

57 **Take S**, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Yamamoto K. Helicobacter pylori eradication may induce de novo, but transient and mild, reflux esophagitis: Prospective endoscopic evaluation. *J Gastroenterol Hepatol* 2009; **24**: 107-113 [PMID: 18823429 DOI: 10.1111/j.1440-1746.2008.05606.x]

58 **Kim N**, Lee SW, Kim JI, Baik GH, Kim SJ, Seo GS, Oh HJ, Kim SW, Jeong H, Hong SJ, Shim KN, Shin JE, Park SJ, Im EH, Park JJ, Cho SI, Jung HC. Effect of Helicobacter pylori Eradication on the Development of Reflux Esophagitis and Gastroesophageal Reflux Symptoms: A Nationwide Multi-Center Prospective Study. *Gut Liver* 2011; **5**: 437-446 [PMID: 22195241 DOI: 10.5009/gnl.2011.5.4.437]

59 **Qian B**, Ma S, Shang L, Qian J, Zhang G. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease. *Helicobacter* 2011; **16**: 255-265 [PMID: 21762264 DOI: 10.1111/j.1523-5378.2011.00846.x]

60 **Weigt J**, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. *Curr Opin Clin Nutr Metab Care* 2009; **12**: 522-525 [PMID: 19584718 DOI: 10.1097/MCO.0b013e32832eb56e]

61 **Lee ES**, Yoon YS, Park CY, Kim HS, Um TH, Baik HW, Jang EJ, Lee S, Park HS, Oh SW. Eradication of Helicobacter pylori increases ghrelin mRNA expression in the gastric mucosa. *J Korean Med Sci* 2010; **25**: 265-271 [PMID: 20119581 DOI: 10.3346/jkms.2010.25.2.265]

62 **Jang EJ**, Park SW, Park JS, Park SJ, Hahm KB, Paik SY, Sin MK, Lee ES, Oh SW, Park CY, Baik HW. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. *J Gastroenterol Hepatol* 2008; **23 Suppl 2**: S278-S285 [PMID: 19120912 DOI: 10.1111/j.1440-1746.2008.05415.x]

**P-Reviewers:** Buzas GM, D'Elios MM, Kim BW, Pimanov SI

**S-Editor:** Zhai HH **L-Editor: E-Edito**r**:**

**Figure 1 Changes in serum pepsinogen levels according to the progress of gastric carcinogenesis.** The pepsinogen II level is increased in the acute stage of *Helicobacter pylori* (*H. pylori*) infection. A pepsinogen II level exceeding 30 ng/dl indicates that the subject has a high risk of diffuse-type gastric cancer. The pepsinogen I level then decreases as the infection progresses to the chronic stage. These features altogether results in the pepsinogen I/II ratio decreasing with the progress of gastric carcinogenesis. A pepsinogen I level below 70 ng/dL and a pepsinogen I/II ratio below 3.0 indicate that the subject has a high risk of intestinal-type gastric cancer. Since the pepsinogen II level is decreased after *H. pylori* eradication to a variable degree, a combination test for serum *H. pylori* antibody and the pepsinogen I/II ratio is not recommended for gastric cancer screening after eradication.

**Figure 2 A metachronous gastric cancer that developed after 6 years of *Helicobacter pylori* eradication.** A 61 year-old South Korean man visited because of epigastric discomfort in March 2007. A: Initial endoscopic finding. Several raised erosions with central ulceration (arrow) were evident. Since H. pylori infection was found by gastric biopsy, eradication was achieved using amoxicillin (1 g), clarithromycin (500 mg), and a a standard dose of proton pump inhibitor twice daily for 7 d; B: Endoscopic finding after 2 years. In June 2009, a gastric adenoma near the pylorus (arrow) was diagnosed by endoscopic biopsy. Complete endoscopic resection was performed; C: Immunohistochemical staining of the resected specimen. Ki-67 staining was positive in the adenoma (Ki-67 stain, x 400); D: Endoscopic finding after 6 years. In January 2013, a slightly depressed lesion was evident on the lesser curvature side of the mid-antrum (arrow); E: Endoscopic submucosal dissection. The lesion was resected since the endoscopic biopsy revealed an adenocarcinoma; F: Pathological finding of the resected specimen. Early gastric cancer type IIc of Lauren’s intestinal-type, moderately-differentiated, tubular adenocarcinoma was diagnosed. The tumor size was 8.0 mm x 6.0 mm x 1.0 mm, and the depth of invasion was limited to the lamina propria (pT1a). Resection margins were free from carcinoma.

**Table 1 Indications for *Helicobacter pylori* eradication in 2013 guidelines**

|  |  |
| --- | --- |
|  | Indications |
| China | Strongly recommended  Peptic ulcer (regardless of activeness or complications)  Gastric MALT lymphoma  Recommended  Chronic gastritis with dyspepsia  Chronic gastritis with mucosal atrophy/erosion  Early gastric cancer resected endoscopically or by subtotal gastrectomy  Long-term use of proton pump inhibitor  Family history of gastric cancer  Planning to take long-term NSAIDs (including low-dose aspirin)  Iron deficiency anemia of unknown causes  Idiopathic thrombocytopenic purpura  Other *H. pylori*-related diseases (lymphocytic gastritis, gastric hyperplastic polyps, Ménétrier disease, *etc.*)  Requested by individual patient |
| Japan | Approved by the Japanese national health insurance system  Peptic ulcer disease  After resection of early gastric cancer  Gastric MALT lymphoma  Idiopathic thrombocytopenic purpura  *H. pylori*-related gastritis |
| South Korea | Strongly recommended  Peptic ulcer disease  Low-grade gastric MALT lymphoma  After resection of early gastric cancer  Recommended  Chronic atrophic gastritis or intestinal metaplasia  Family history of gastric cancer.  Functional dyspepsia  Long-term aspirin/NSAIDs medication with history of peptic ulcer disease  Idiopathic thrombocytopenic purpura |

*H. pylori*: *Helicobacter pylori*; MALT: Mucosa-associated lymphoid tissue; NSAIDs: Nonsteroidal anti-inflammatory drugs.

**Table 2 Diagnostic methods for *Helicobacter pylori* infection in 2013 guidelines**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | China | Japan | South Korea |
| For initial diagnosis | Non-invasive methods | Urea breath test  Stool antigen test | Serum antibody test  Urea breath test  Stool antigen test | Serum antibody test  Urea breath test  Stool antigen test |
| Invasive methods | Rapid urease test  Histology  Culture | Rapid urease test  Histology  Culture | Rapid urease test  Histology |
| Follow-up test after eradication | Non-invasive methods | Urea breath test  Stool antigen test | Serum antibody test1  Urea breath test  Stool antigen test | Urea breath test  Stool antigen test |
| Invasive methods | Rapid urease test | Rapid urease test  Histology  Culture | Rapid urease test  Histology |

1In Japan, a decrease relative to the initial antibody titer of more than 50% after 6-12 mo is considered to be the most accurate method for determining successful eradication. Since the Japanese national health insurance system covers 2 of 3 non-invasive tests at the same time, either “serology with the urea breath test” or “serology with the stool antigen test” is usually performed before and after *Helicobacter pylori* eradication.

**Table 3 Regimens for *Helicobacter pylori* eradication in 2013 guidelines**

|  |  |  |  |
| --- | --- | --- | --- |
|  | China | Japan | South Korea |
| First-line treatment1 | Amoxicillin 1 g (or metronidazole 400 mg), clarithromycin 500 mg, and PPI twice daily for 7-14 d | Amoxicillin 750 mg, clarithromycin 200 mg (or 400mg), and PPI twice daily for 7 d | Amoxicillin 1 g, clarithromycin 500 mg, and PPI twice daily for 7-14 d |
| Second-line treatment | Bismuth 220 mg, tetracycline 750 mg, metronidazole 400 mg twice, and PPI twice daily for 10 or 14 d | Amoxicillin 750 mg, metronidazole 250 mg, and PPI twice daily for 7 d | Bismuth 120 mg four times, tetracycline 500 mg four times, metronidazole 500 mg thrice, and PPI twice daily for 7-14 d |

1In China and South Korea, first-line treatment can be passed directly to second-line treatment using bismuth-based quadruple therapy in cases with a high clarithromycin resistance rate (> 15%–20%). PPI: Proton pump inhibitor.

**Table 4 Different characteristics of 2013 guidelines in three countries**

|  |  |  |
| --- | --- | --- |
|  | Country | Notable differences in characteristics |
| Indication for eradication | China | Strong recommendations do not include after resection of EGC. Intestinal metaplasia is not included in the indications. |
| Japan | All infected subjects are included as “*H. pylori*-related gastritis.”  Focus is on preventing dissemination. |
| South Korea | Strong recommendations include only peptic ulcer disease, gastric MALT lymphoma, and after resection of EGC. |
| Diagnostic method | China | Serology is not recommended.  Only the urea breath test is recommended after eradication.  Invasive tests are not recommended after eradication. |
| Japan | Either two noninvasive tests or one invasive test is recommended.  A decrease relative to the initial serum antibody level of more than 50% after 6-12 mo is considered the most reliable method. |
| South Korea | Bacterial culture is not included. |
| Treatment regimen | China | Due to the high resistance to the antibiotics metronidazole, clarithromycin, and tetracycline, an alternative regimen is recommended.  First-line treatment can be omitted in cases of clarithromycin resistance. |
| Japan | Lower dose of antibiotics for shorter duration (7 d) than other countries.  There is neither 14 d nor bismuth-based regimen in the first-line and second-line treatment. |
| South Korea | First-line treatment can be omitted in cases of clarithromycin resistance. |

EGC: Early gastric cancer; *H. pylori*: *Helicobacter pylori*; MALT: Mucosa-associated lymphoid tissue.